Latest Breaking News On - ராபர்ட் பொசடமக - Page 1 : comparemela.com

Ziopharm Oncology Announces Election of Robert Postma to its Board of Directors

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Ziopharm Oncology Announces Election of Robert Postma to its Board of Directors ZIOPHARM Oncology IncFebruary 5, 2021 GMT BOSTON, Feb. 05, 2021 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and long-term shareholder of Ziopharm. James Huang, Chairman of the Board, said, “We welcome Bob to Ziopharm’s Board of Directors. With his experience and financial acumen, Bob will make an immediate contribution to Ziopharm and I believe the Board is now well positioned to partner with the management team to deliver on our very promising T-cell directed and cytokine technologies and opportunities.”

United statesPatrick burseyLaurence cooperEden biocellJames huangRobert postmaRegeneron pharmaceuticalsZiopharm oncology incNational cancer instituteCompany nasdaqUniversity of texas md anderson cancer centerDrug administrationExchange commissionLifesci communicationsCorporate communicationsWatermill asset management

Why Ziopharm Oncology Stock Is Soaring Today

Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights What happened Shares of Ziopharm Oncology (NASDAQ:ZIOP) were soaring 11.8% as of 11:45 a.m. EST on Friday. The nice gain came after the company announced the election of Robert Postma to its board of directors. The addition expanded Ziopharm s board from eight members to nine. So what The election of new board members doesn t usually provide a catalyst for a biotech stock. What s different in this case?

Laurence cooperRobert postmaZiopharm oncologyWatermill assetScott tarriffலாரன்ஸ் கூப்பர்ராபர்ட் பொசடமகவாட்டர் மில் சொத்து

Egan-Jones Recommends Against Electing Dissident s Full Slate of Nominees to Ziopharm Board Nasdaq:ZIOP

s Independent financial analysts widely recognize this progress: “ZIOP continues to make progress with respect to the company-sponsored TCR-T program, the Controlled IL-12 program, and the Sleeping Beauty CAR-T program.” 2 “By unlocking the potential of its Sleeping Beauty technology, the Company is poised to deliver a leap forward in the personalization of cancer therapy.” 3 “We think that the company continues to make forward progress across its various platforms (TCR-T, CAR-T, and controlled IL-12).ZIOP has executed well over 2020 in curating immune receptors from its own libraries and it is moving forward its wholly owned program.” 4 The Company continues to urge shareholders to support Ziopharm’s continued progress and protect the value of their investment by signing and returning the

United statesChris kittredgeRaymond jamesZachary tramontiAndrew coleMichael verrechiaHolger weisJ kevin buchiJaime vieserRobertw postmaRobert postmaServices egan jonesZiopharm oncology incNational cancer instituteUniversity of texas md anderson cancer centerWatermill asset management corp

Egan-Jones Recommends Against Electing Dissident s Full Slate of Nominees to Ziopharm Board Seite 1

Egan-Jones Recommends Against Electing Dissident s Full Slate of Nominees to Ziopharm Board Seite 1
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Holger weisJaime vieserisRobert postmaInstitutional shareholder servicesஹோல்கர் வெயிஸ்ராபர்ட் பொசடமகநிறுவன பங்குதாரர் சேவைகள்